N-Acetyl-L-glycine (CAS 543-24-8; C₄H₇NO₃; molar mass 117.10 g/mol; melting range 206–208 °C), also recorded in older literature as aceturic acid, is handled as an N-protected glycine equivalent in solution-phase peptide coupling units. The L descriptor is retained in some supplier nomenclatures despite the absence of a stereocentre; optical rotation is not a release parameter. The N-acetyl terminus is retained as the final peptide cap rather than removed, which restricts its use to acetylated peptide fragments and certain protected glycinamide intermediates. In a standard production batch, the acid is activated in anhydrous DMF or dichloromethane at 0–5 °C with 1.05 mol of N,N’-diisopropylcarbodiimide and 1.0 mol of 1-hydroxybenzotriazole per mole of N-acetylglycine, with 1.0 mol of diisopropylethylamine added to maintain a non-protic base environment. A jacketed glass-lined reactor with bottom discharge, nitrogen overlay, and external cooling loop charges the acid, solvent, HOBt, and base; the mixture is held for 30 min before the C-protected amino acid hydrochloride is added as a single portion. Reaction progress is followed by HPLC on a C18 column, 150 mm × 4.6 mm, 5 µm particle size, with UV detection at 214 nm. Residual N-acetylglycine below 1.0 % area triggers phase separation and aqueous bicarbonate wash. Water content in the coupling solvent is kept below 0.05 % to suppress hydrolysis of the activated ester; because the glycine residue has no chiral centre, epimerisation is not monitored at that position, but the C-terminal amino acid ester still requires moisture control. The crude protected peptide is crystallised from hot ethyl acetate/heptane; absence of diisopropylurea is confirmed by proton nuclear magnetic resonance and by the absence of the urea carbonyl band in the 1,550–1,650 cm^-1 infrared window. Batch records are maintained under ICH Q7, with cleaning validation under ICH Q7 Section 12.4; residual solvents are reported according to USP <467>. Terminal streams include acetyl-glycyl dipeptide esters and acetyl-capped oligopeptide intermediates destined for API manufacturers, not for direct formulation.

What Limits Enzymatic Hydrolysis Assays Using N-Acetyl-L-Glycine?

Enzymatic screening programmes use N-acetyl-L-glycine as a substrate probe for aminoacylase I (EC 3.5.1.14), the zinc-binding hydrolase that cleaves N-acyl amino acids to acetate and the free amino acid. The compound is classified as a slow substrate relative to N-acetyl-L-methionine; published kinetic data for N-acetylglycine are restricted, and catalytic activity has been shown to depend on metal cofactor load, buffer chelator content, and substrate purity. Assay workflows prepare a 100 mM stock solution in 50 mM Tris-HCl, pH 7.5, then dilute to final concentrations from 0.1 mM to 10 mM. Released glycine is derivatised with o-phthalaldehyde in the presence of 3-mercaptopropionic acid and quantified by fluorescence detection at excitation 340 nm and emission 455 nm; detector response is linear from 0.05 mM to 1.00 mM for glycine standards prepared in the same buffer matrix. Because glycine is achiral, enantioselective hydrolysis cannot be evaluated with this substrate; acylase inhibition studies therefore pair N-acetyl-L-glycine with N-acetyl-L-methionine to distinguish active-site steric effects from metal-binding inhibition. Trace contamination with free glycine above 0.05 % in the substrate creates elevated blanks and reduces the reliable signal window in high-throughput microplate formats. The enzymatic reaction is stopped after 20 min at 25 °C by addition of trichloroacetic acid to a final concentration of 5 %. Clarified reactions are then centrifuged at 10,000 × g for 10 min before plate reading. Standard operating procedures follow ISO 9001 for research support work; where the assay supports diagnostic biomarker validation, laboratory quality requirements are managed under ISO 15189. Terminal deliverables are kinetic screening data and glycine release rate constants rather than isolated downstream products.

In cosmetic peptide manufacturing, the N-acetyl group is introduced at the terminal glycine position before assembly of low-molecular-weight oligopeptide actives. The resulting acetyl-capped glycine-containing peptide is used as a skin-conditioning raw material in leave-on emulsions; the starting N-acetyl-L-glycine is consumed as a building block rather than added as the final active. The peptide synthesis train follows ISO 22716:2007 for cosmetic Good Manufacturing Practice and requires traceability of incoming N-acetyl-L-glycine to the designated supplier audit file. Residual uncoupled N-acetyl-L-glycine in the peptide intermediate is controlled at or below 0.10 % by HPLC at 214 nm; the residual solvent profile is tested under USP <467> or an equivalent gas-chromatographic method. A typical purification sequence involves reverse-phase preparative chromatography on C8-modified silica with a water/acetonitrile gradient containing 0.1 % trifluoroacetic acid; the TFA salt is then exchanged to the acetate salt on an anionic resin column. Final peptide active powders are freeze-dried at a chamber pressure below 0.1 mbar and stored under argon at -20 °C. In the downstream emulsion, the acetylated peptide active is added to the cooled water phase at 0.0001–0.0010 % by weight as dry peptide content after the emulsion has cooled below 40 °C; high-shear mixing above 10,000 rpm is avoided because air entrainment accelerates oxidation of methionine or cysteine residues in sulfur-containing peptide sequences. Cosmetic safety documentation is prepared under Regulation (EC) No 1223/2009, with the peptide actives covered by the Article 10 safety assessment. REACH registration under Regulation (EC) No 1907/2006 applies to the starting acid as an imported substance. Terminal finished goods include leave-on serums and cream-gel textures marketed as cosmetic products without drug claims.

Azlactone Activation as a Route to Substituted Glycinamides

Cyclodehydration of N-acetyl-L-glycine with acetic anhydride produces 2-methyl-5(4H)-oxazolone, referred to as the acetyl glycine azlactone. In batch synthesis, 1.0–1.2 mol of acetic anhydride per mole of N-acetylglycine is charged to a jacketed glass reactor equipped with a distillative head; the temperature is raised to 60–80 °C and held until the water of reaction is removed, with or without toluene as entrainer. The water content in the returning distillate must fall below 0.10 % before ring-opening nucleophile addition. The azlactone is moisture-sensitive; exposure to atmospheric humidity hydrolyses the five-membered ring back to N-acetylglycine, which can be tracked by the reappearance of the free carboxyl stretch near 1,700 cm^-1 in infrared monitoring. Ring-opening with primary amines is performed at 0–5 °C in anhydrous THF or dioxane to suppress oxazolone polymerisation; the addition of 1.0–1.1 mol of amine is followed by warming to 20–25 °C over 2 h. The isolated substituted N-acetylglycinamide is washed with 5 % sodium bicarbonate and vacuum-dried at 40–50 °C. This route avoids carbodiimide-derived urea by-products, but it is limited to N-acyl amino acids and cannot be applied to free peptide chains bearing base-labile side-chain protection. Process safety review is required because acetic anhydride is corrosive and the azlactone may have sensitising potential; engineering controls include closed transfer, nitrogen inerting, and scrubbers rated for organic acid vapours. Emissions from the distillation step are controlled under local volatile organic compound regulations, with stack testing performed according to EN 12619 where applicable. Terminal products include N-acetyl-glycine amides and hydrazides used as intermediates in medicinal chemistry and protected building-block derivatisation.

For ester and acid chloride derivatisation, the carboxyl group of N-acetyl-L-glycine is activated in a glass-lined reactor under inert conditions. N-Acetylglycine ethyl ester is prepared by Fischer esterification with anhydrous ethanol saturated with hydrogen chloride at 0–5 °C, followed by slow warming to 20–25 °C over 12–18 h; excess alcohol is stripped under vacuum at 40 °C, and the crude ester is crystallised from ethyl acetate/hexane. The purified ester is used as an intermediate in substituted glycinamide synthesis and in enolate alkylation studies. For conversion to N-acetylglycyl chloride, the acid is suspended in dichloromethane and treated with 1.2 mol of thionyl chloride per mole of acid at 0–5 °C in the presence of catalytic dimethylformamide. Hydrogen chloride and sulfur dioxide evolved during the reaction are directed to an alkaline scrubber; reactor pressure is maintained slightly negative to avoid acid gas breakthrough. The resulting acid chloride is unstable in the presence of moisture and must be used in situ or within 6 h when stored at -20 °C under nitrogen. Amidation is carried out by slow addition of the acid chloride solution to a solution of the amine and 1.1 mol of triethylamine in dichloromethane at -10–0 °C; the neutralising base is held at no more than 10 % excess to minimise chloroacetate by-products. The reaction mass is washed with cold 0.1 M hydrochloric acid and saturated sodium chloride; the organic phase is dried over magnesium sulfate and concentrated on a rotary evaporator below 35 °C. Process effluent containing thionyl chloride-derived sulfite and sulfate species is treated to pH 6.5–8.0 before discharge; pH is verified with a calibrated meter traceable to NIST reference materials. Terminal products are N-acetylglycine ethyl ester and N-acetylglycyl chloride intermediates for subsequent coupling or heterocycle synthesis.

When Sodium Salt Formation Is Required for Downstream Processing

Neutralisation of N-acetyl-L-glycine with 30 % aqueous sodium hydroxide follows a pH-stat protocol in a jacketed stainless steel or glass-lined reactor fitted with an in-line pH electrode and automated dosing pump. The acid is slurried in deionised water at 20–25 °C; NaOH is dosed at a rate that holds pH between 7.0 and 7.5. Over-addition above pH 8.0 accelerates amide hydrolysis and can generate sodium glycinate after prolonged hold, which is detectable by ninhydrin-positive free glycine in the mother liquor. The resulting sodium N-acetylglycinate solution is clarified through a 0.2 µm filter and either concentrated on a falling-film evaporator at 50–60 °C under reduced pressure or spray-dried. Spray drying with a rotary atomiser at inlet air temperature 160–180 °C and outlet temperature 70–80 °C produces a free-flowing powder; bulk density is measured with a tapped density tester under USP <616> and typically falls in the range 0.35–0.55 g/mL, but site-specific qualification data control the release specification. Hygroscopicity of the dried salt requires packaging in double polyethylene-laminated aluminium foil bags with a moisture vapour transmission rate below 0.10 g/m²/day; storage is specified at 15–25 °C and relative humidity below 40 %. The salt form is produced for solubilising the acid in aqueous feedstocks or for direct use in peptide synthesis charging systems that avoid dust generation. Published data describing spray-dried sodium N-acetylglycinate end-use performance are limited; process parameters are therefore qualified within the contract manufacturing organisation rather than extrapolated from literature. Cleaning validation after salt campaigns is conducted under ICH Q7 Section 12.4 because the same equipment may process pharmaceutical intermediates; total organic carbon swab limits are set at 10 ppm or lower. Terminal product is not sold as a formulated article but as a solid intermediate for subsequent chemical conversion.